Renal Cell Carcinoma
Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. T...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_58186 | ||
| 005 | 20210212 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210212s2020 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03928-639-3 | ||
| 020 | |a 9783039286386 | ||
| 020 | |a 9783039286393 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03928-639-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a López, José I. |4 auth | |
| 245 | 1 | 0 | |a Renal Cell Carcinoma |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (500 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70-80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe-oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a N-glycomapping | ||
| 653 | |a n/a | ||
| 653 | |a SMAD proteins | ||
| 653 | |a patient survival | ||
| 653 | |a pro-IL-1? | ||
| 653 | |a survival prediction | ||
| 653 | |a inflammation markers | ||
| 653 | |a tumor migration | ||
| 653 | |a prognostic factors | ||
| 653 | |a practical approach | ||
| 653 | |a circular RNAs in a clinico-genomic predictive model | ||
| 653 | |a glycomarkers | ||
| 653 | |a review | ||
| 653 | |a nephrectomy | ||
| 653 | |a uric acid | ||
| 653 | |a VEGF inhibitors | ||
| 653 | |a metabolic reprogramming | ||
| 653 | |a collecting duct carcinoma | ||
| 653 | |a curcumin | ||
| 653 | |a metabolome profiling | ||
| 653 | |a identification of circular RNAs | ||
| 653 | |a IL-2 | ||
| 653 | |a experimental validation of circular RNA | ||
| 653 | |a Raf/MEK/ERK | ||
| 653 | |a HOT | ||
| 653 | |a PI3K/Akt/mTOR | ||
| 653 | |a pentose phosphate pathway | ||
| 653 | |a kidney cancer | ||
| 653 | |a LOT | ||
| 653 | |a mutation | ||
| 653 | |a RCC | ||
| 653 | |a polybromo-1 | ||
| 653 | |a pale cell | ||
| 653 | |a MMP-9 | ||
| 653 | |a gene expression | ||
| 653 | |a recurrence free survival | ||
| 653 | |a chromosomal loss | ||
| 653 | |a IL-1? | ||
| 653 | |a chronic kidney disease | ||
| 653 | |a glutathione transferase omega 2 | ||
| 653 | |a label-free | ||
| 653 | |a glutathione transferase omega 1 | ||
| 653 | |a emerging entity | ||
| 653 | |a copy number alteration | ||
| 653 | |a FOXO3 | ||
| 653 | |a predictive role | ||
| 653 | |a tumor slice culture | ||
| 653 | |a tyrosine kinase inhibitors | ||
| 653 | |a PPP | ||
| 653 | |a ESC | ||
| 653 | |a CDKN1A expression | ||
| 653 | |a metastasis | ||
| 653 | |a PD-L1 | ||
| 653 | |a diagnostic and prognostic markers | ||
| 653 | |a EVI1 | ||
| 653 | |a copy number loss | ||
| 653 | |a RNA sequencing | ||
| 653 | |a NK cells | ||
| 653 | |a glutathione metabolism | ||
| 653 | |a clear cell renal cell carcinoma | ||
| 653 | |a renal cell cancer | ||
| 653 | |a proliferation | ||
| 653 | |a eosinophilic variant | ||
| 653 | |a Xp11 translocation renal cell carcinoma | ||
| 653 | |a prognosis | ||
| 653 | |a invasion | ||
| 653 | |a immune infiltration | ||
| 653 | |a IL4R? | ||
| 653 | |a FISH | ||
| 653 | |a 11) translocation renal cell carcinoma | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a metabolome | ||
| 653 | |a hyperosmolality | ||
| 653 | |a toxicity | ||
| 653 | |a ALK | ||
| 653 | |a drug sensitivity | ||
| 653 | |a t(6 | ||
| 653 | |a copy number analysis | ||
| 653 | |a urine | ||
| 653 | |a genetic association | ||
| 653 | |a polymorphism | ||
| 653 | |a solute carrier proteins | ||
| 653 | |a kidney | ||
| 653 | |a metastatic ccRCC | ||
| 653 | |a molecular genetic features | ||
| 653 | |a recurrence-free survival | ||
| 653 | |a chromophobe renal cell carcinoma | ||
| 653 | |a unclassified renal tumor | ||
| 653 | |a overall survival | ||
| 653 | |a mTOR inhibitors | ||
| 653 | |a mTOR | ||
| 653 | |a JAK2 | ||
| 653 | |a von Hippel-Lindau | ||
| 653 | |a miR-155-5p | ||
| 653 | |a glycoproteomics | ||
| 653 | |a PBRM1 | ||
| 653 | |a miR-133b | ||
| 653 | |a survival | ||
| 653 | |a TFE3 | ||
| 653 | |a TFEB | ||
| 653 | |a oncocytic renal tumor | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a biomarker | ||
| 653 | |a MMP10 | ||
| 653 | |a TCGA | ||
| 653 | |a ghrelin | ||
| 653 | |a EMT like | ||
| 653 | |a checkpoint inhibitors | ||
| 653 | |a MiT family translocation renal cell carcinoma | ||
| 653 | |a gene signature | ||
| 653 | |a sarcomatoid | ||
| 653 | |a transforming growth factor beta | ||
| 653 | |a clear cell Renal Cell Carcinoma | ||
| 653 | |a tumor adhesion | ||
| 653 | |a renal cancer | ||
| 653 | |a unclassified renal cell carcinoma | ||
| 653 | |a Papillary renal cell carcinoma (pRCC) | ||
| 653 | |a miR-146a-5p | ||
| 653 | |a renal cell | ||
| 653 | |a everolimus | ||
| 653 | |a integrins | ||
| 653 | |a cytoreductive nephrectomy | ||
| 653 | |a immunotherapy | ||
| 653 | |a predictive factors | ||
| 653 | |a immunohistochemistry | ||
| 653 | |a MTA2 | ||
| 653 | |a IL13R?1 | ||
| 653 | |a targeted therapy | ||
| 653 | |a intratumour heterogeneity | ||
| 653 | |a aurora A | ||
| 653 | |a TCA cycle | ||
| 653 | |a AMP-activated protein kinases | ||
| 653 | |a cancer-specific survival | ||
| 653 | |a programmed death-ligand 1 | ||
| 653 | |a efficacy | ||
| 653 | |a renal cell carcinoma | ||
| 653 | |a anaplastic lymphoma kinase rearrangement | ||
| 653 | |a TFEB-amplified renal cell carcinoma | ||
| 653 | |a statins | ||
| 653 | |a cancer immunotherapy | ||
| 653 | |a microRNA | ||
| 653 | |a new entity | ||
| 653 | |a proteome profiling | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2229 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/58186 |7 0 |z DOAB: description of the publication |